Research is ongoing to find new, safe, effective treatments for COVID-19.

​

Available treatments include:

​​

• Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use, available by prescription only) - antiviral with Emergency Use Authorization from FDA for the treatment of mild-to-moderate coronavirus disease (COVID-19) in patients who meet all of the following criteria:

  • adults and children age 12+

  • weight of at least 40 kilograms or 88 pounds

  • tested positive for COVID-19

  • symptoms started no more than 5 days ago

  • are at high risk for progression to severe COVID-19

​

• Molnupiravir - oral antiviral medication with Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 infection in patients age ≥18 years who are at high risk of disease progression AND who are unable to use Paxlovid or remdesivir. Treatment should be initiated as soon as possible and within 5 days of symptom onset.

​

• Remdesivir (Veklury) - antiviral medication administered intravenously (IV) to patients whose symptoms are severe enough to require hospitalization. 

​

• Other medications and treatment protocols for hospitalized patients depend on the severity of illness, underlying medical conditions, and comorbidities at the time of hospitalization.

​

• Multiple new treatments are being developed and evaluated. Some treatments which received emergency use authorization and were effective for earlier COVID variants are no longer effective against more recent variants and therefore are no longer in use in most areas. These include several monoclonal antibody infusions.

 

While there has been much press coverage of medications such as Plaquenil (hydroxychloroquine) and ivermectin, these are NOT recommended for treatment or prophylaxis against COVID-19.

​